Key Takeaways
- Record EBITDA, margin jump: Q1 delivered the highest EBITDA in 40 years at ₹55.05 cr, with margins expanding from ~7% to 12% on softer raw material costs and backward integration.
- Devices annuity engine scales: 1.23 cr installed glucometers drove 12 cr strip sales in Q1 alone, while BP monitors are on track to cross ₹100 cr this year after 100% backward integration.
- QIP unlocks Morepen 2.0: The ₹200 cr raise, the first capital event in ~30 years, brought in marquee institutional investors and funds a capacity expansion cycle across APIs and devices.
- Export pivot underway: Exports grew 31%, led by Europe at +130%, while the domestic pharma mix was intentionally reduced. Medical device export certifications are 2-3 years out.
- What to watch next quarter: The weight loss product launch timed for the festival season, the pace of capacity expansion commercialization from Q3/Q4, and whether the margin trajectory holds as backward integration deepens.
Medical Devices: The Annuity Moat
- Installed base lock-in: 1.23 cr glucometers in the field create a printer-cartridge model where only Morepen strips work on Morepen meters, generating recurring, locked-in revenue.
- Strip volume acceleration: 12 cr strips were sold in Q1 alone, against 36 cr for the full prior year, signaling a sharp step-up in the recurring pull-through from the growing meter base.
- BP monitors scaling fast: Revenue hit ₹26 cr in Q1 versus ₹80 cr for all of last year, with 100% backward integration now complete via dedicated SMT lines and in-house chip mounting.
- Counterfeit risk: The brand's visibility has attracted counterfeit products on marketplaces like Amazon, prompting packaging redesigns, new holograms, and customer awareness pushes. Government QR code guidelines are in the works.
Sushil Suri: "It's like a typical printer cartridge model. And this is a locked-in system. Our meter can use only our strips, and our strips work only on our meters. So that way, it's like a regular annuity business."
Margin & Profitability Reset
- Gross margin tailwind: Softening intermediate prices from China, where post-COVID warehouses are fully stocked with no demand, helped Morepen regain price levels and expand gross margins. The company is strategizing to sustain higher margins rather than depend on China.
- Backward integration payoff: Manufacturing devices from bare chips with robotic in-house chip mounting, plus dedicated SMT lines for BP monitors, is structurally lifting device margins.
- Blended margin ambition: Management expects a 3-4% EBITDA margin improvement over the next two to three years, moving from the current 12% toward 15%, though it declined to commit to a specific quarter or year.
- PAT target: Double-digit PAT margins are the goal over the next three years, with the current tax rate around 26% expected to hold.
API Business & Export Shift
- Global market leadership: Morepen is number one globally in Loratadine, Desloratadine, and Montelukast by capacity and export revenue, and number one in exports for Fexofenadine.
- Export mix transformation: Europe grew 130% and South America 80%, while the U.S. dropped 33% on a high base and India was intentionally reduced 16% due to lower yields and price drops.
- New product pipeline: Sitagliptin, Linagliptin, Dapagliflozin, and Empagliflozin are growing and expected to reach 30-35% of API revenue by 2030, up from 15% currently.
- China Plus One readiness: New API capacity expanding from 400 KL to 600 KL will position the company to capture global supply chain shifts away from China.
Capacity Expansion & Capex
- 18-month build cycle: New capacities across APIs, glucometers, and BP monitors are expected to be fully operational within 12 to 18 months, with civil work on chip backward integration already complete.
- Commercialization cadence: Backward integration of chips is targeted during this financial year, with capacity expansion results becoming visible from Q3/Q4 onward.
- Asset turnover dynamics: API asset turnover of 7.2 is expected to be maintained or improved with new modern machinery, while devices turnover, currently 10.5, is expected to stabilize around 8.5-9 after backward integration increases in-house manufacturing.
- Working capital watch: Devices working capital days are around 70, APIs at 90-plus. Working capital may increase in devices as backward integration deepens in-house manufacturing.
New Initiatives & Distribution
- Weight loss product launch: A weight loss product sourced from a UK joint venture is set to launch between September and October, targeting the festival season. Morepen will handle distribution and marketing, aiming at the at-home consumer rather than the doctor-channel injectables market.
- Retail expansion ambition: The company aims to grow from 128,000 retail outlets to 3 lakh outlets over the next three years, with a particular push into South and West India where it remains underpenetrated relative to its North and East stronghold.
- KBC brand push: Dr. Morepen glucometer ads are running on Kaun Banega Crorepati with Amitabh Bachchan, placed on the desktop in front of the host and candidate, targeting the show's mass family audience.
- Facility audits progressing: One major global retailer and one Korean company have completed facility audits, laying the groundwork for future export certifications in medical devices.
Sushil Suri: "Most of the companies are focusing on the doctors' chamber and of course the products are very costly, semaglutide, liraglutide. So many products are being talked and there are injectables also. But we have seen the trend, the consumer still wants something at home in the comfort of home, which he can follow at peace."
The Morepen 2.0 Thesis
- QIP breaks a 30-year drought: The ₹200 cr raise, with 3.68 cr new shares issued, is the first capital event in roughly three decades and marks the transition to a debt-free growth phase.
- Institutional validation: Bank of America, Samsung, Citigroup, Societe Generale, Nomura, BNP Paribas, Morgan Stanley, and Eminence participated, lifting institutional holding to 10.61-10.67%.
- Acquisition optionality: No immediate plan exists for the QIP proceeds, but management is open to acquisitions that add synergy and strategy, and is evaluating multiple things while preserving a cash surplus.
- Global devices opportunity: Management views India as just 3-5% of the global market, with the real jump coming if export certifications open the rest of the world in the next two to three years.
Sushil Suri: "This is Morepen 2.0. Like whatever we have done in the past, so we, of course, as a debt-free company, cleared all the debts. And now we are in a growth phase with the new capital in hand."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 15-20% top-line growth | Ongoing (consistent with historical 18% CAGR) |
| EBITDA margin expansion | 3-4% improvement from current ~12% toward 15% | Over the next 2-3 years |
| PAT margin | Reach double-digit PAT margins | Over the next three years |
| Capacity operational | New API (400 KL to 600 KL), glucometer, and BP monitor capacities fully operational | Within 12-18 months |
| BP monitor revenue | Cross ₹100 cr (vs ₹80 cr last year) | This fiscal year |
| Chip backward integration | Commercialization of in-house chip manufacturing | During this financial year |
| Retail outlet expansion | Grow from 128,000 to 3 lakh retail outlets | Over the next three years |
| API product mix shift | New products (Sitagliptin, Linagliptin, Dapagliflozin, Empagliflozin) reach 30-35% of API revenue | By 2030 |
| Medical devices export dominance | Exports become dominant in medical devices business | In another 2-3 years, after certifications |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Gross revenue | ₹458.64 cr, +14% YoY |
| Pharma revenue | ₹320 cr, +11% YoY |
| Medical devices revenue | ₹138 cr, +20% YoY |
| Medical devices share of revenue | 30.2%, up from 26% last fiscal |
| EBITDA | ₹55.05 cr, +93% YoY, highest ever in 40 years |
| EBITDA margin | 12%, up from 7.07% in Q1 last year |
| Profit before tax | +135% YoY |
| Profit after tax | ₹36 cr, +147% YoY, vs ₹14.63 cr last year |
| PAT margin | 7.89%, up from 3.63% in Q1 last year |
| EPS (TTM) | ₹2.30, up from ₹1.88 as on financial closing |
| EPS (Q1 FY25) | ₹0.71 per share |
| Export business growth | +31% YoY |
| Cash generation | ₹53 cr, +91% YoY |
| Medical devices installed meter base | 1.23 cr meters |
| Glucose strips sold | 12 cr strips in Q1, vs 36 cr strips in all of last year |
| BP monitors revenue | ₹26 cr in Q1, vs ₹80 cr in all of last year |
| BP monitors growth | 29% YoY |
| Glucometers growth | 17% YoY |
| API market share: Loratadine | 67% |
| API market share: Montelukast | 44% |
| API market share: Desloratadine | 26% |
| API market share: Fexofenadine | 22% |
| API export share | 71% of API business |
| Europe API growth | +130% YoY |
| South America API growth | +80% YoY |
| U.S. API growth | -33% YoY, due to high base |
| India API growth | -16% YoY, purposeful reduction |
| QIP amount raised | ₹200 cr, 3.68 cr new shares issued |
| Institutional holding | 10.61%–10.67%, up from 3%–4% earlier |
| Capex from QIP proceeds | ₹123 cr allocated |
| API capacity expansion | 400 KL to 600 KL |
| Glucometer capacity expansion | 0.25 cr to 0.5 cr units |
| Glucose strips capacity expansion | 50 cr to 70 cr units |
| BP monitor capacity expansion | 0.12 cr to 0.25 cr units |
| Tax rate | ~26% |
| Asset turnover: API | 7.2 |
| Asset turnover: Medical devices | ~10.5, expected to stabilize at 8.5–9 after backward integration |
| Working capital days: Medical devices | ~70 days last fiscal |
| Working capital days: API | 90+ days |
| Retail outlets | 128,000 currently, targeting 3 lakh in three years |
| Revenue growth expectation | 15%–20% (Sushil Suri), 15%–18% (Ajay Sharma) |